ABSTRACT

Description: Trastuzumab is a humanized monoclonal antibody with binding activity for the human epidermal growth factor receptor 2, HER2, which is found on the surface of metastatic breast cancer cells. Herceptin is expressed in mammalian cells and is supplied in a lyophilized form (150 mg/vial) to be reconstituted and diluted before administration as an infusion.